FDA to Hold Public Meeting on Benefit-Risk Assessment of Medical Products, Seeks Public Comment

Summary

The FDA is hosting a public meeting to gather input on its Benefit-Risk Framework for new drugs and biologics, with the goal of developing a draft guidance and a publicly available summary report, in accordance with its commitment under the Prescription Drug User Fee Amendments of 2017.